Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients

References

• Youn YS, Bae YH. Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Deliv Rev. 2018;130:3–11.
   PubMed Web of Science ®Google Scholar
• Soares S, Sousa J, Pais A, et al. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies in anticancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38.
   PubMed Web of Science ®Google Scholar
• Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Brayden DJ. Development of nanotoxicology: implications for drug delivery and medical devices. Nanomedicine. 2015;10(14):2289–2305.
   PubMed Web of Science ®Google Scholar
• Shen SH, Wu YS, Liu YC, et al. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine. 2017;12:4085–4109.
   PubMed Web of Science ®Google Scholar
• Severino P, da Silva CF, Andrade LN, et al. Alginate nanoparticles for drug delivery and targeting. Curr Pharm Design. 2019;25(11):1312–1334.
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71.
   PubMed Web of Science ®Google Scholar
• Velino C, Carella F, Adamiano A, et al. Nanomedicine approaches for the pulmonary treatment of cystic fibrosis. Front Bioeng Biotechnol. 2019;7:406.
   PubMed Web of Science ®Google Scholar
• Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299–319.
   PubMed Web of Science ®Google Scholar
• Irby D, Du C, Li F. Lipid-drug conjugate for enhancing drug delivery. Mol Pharm. 2017;14(5):1325–1338.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kesarla R, Chotai N, et al. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int. 2017;2017:5984014.
   PubMed Web of Science ®Google Scholar
• Van Haute D, Jiang W, Mudalige T. Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation. Int J Pharm. 2019;569:118603.
   PubMedGoogle Scholar
• Brough C, Miller DA, Keen JM, et al. Use of polyvinyl alcohol as a solubility-enhancing polymer for poorly water soluble drug delivery (Part 1). AAPS PharmSciTech. 2016;17(1):167–179.
   PubMedGoogle Scholar
• Kadajji VG, Betageri GV. Water soluble polymers for pharmaceutical applications. Polymers. 2011 Dec;3(4):1972–2009.
   Web of Science ®Google Scholar
• Franco P, De Marco I. The use of poly(N-vinyl pyrrolidone) in the delivery of drugs: a review. Polymers. 2020;12(5):5.
   Web of Science ®Google Scholar
• Mašková E, Kubová K, Raimi-Abraham BT, et al. Hypromellose – A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. J Control Release. 2020;324:695–727.
   PubMed Web of Science ®Google Scholar
• Pottel J, Armstrong D, Zou L, et al. The activities of drug inactive ingredients on biological targets. Science. 2020;369(6502):403–413.
   PubMed Web of Science ®Google Scholar
• Dormont F, Rouquette M, Mahatsekake C, et al. Translation of nanomedicines from lab to industrial scale synthesis: the case of squalene-adenosine nanoparticles. J Control Release. 2019;307:302–314.
   PubMed Web of Science ®Google Scholar
• Dagtepe P, Chikan V. Quantized Ostwald ripening of colloidal nanoparticles. J Phys Chem C. 2010;114(39):16263–16269.
   Web of Science ®Google Scholar
• Ball RL, Bajaj P, Whitehead KA. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int J Nanomedicine. 2016;12:305–315.
   PubMed Web of Science ®Google Scholar
• Colino CI, Lanao JM, Gutierrez-Millan C. Targeting of hepatic macrophages by therapeutic nanoparticles. Front Immunol. 2020;11:218.
   PubMed Web of Science ®Google Scholar
• Im H-J, England CG, Feng L, et al. Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated nanoparticles in peripheral arterial disease. ACS Appl Mater Interfaces. 2016;8(28):17955–17963.
   PubMed Web of Science ®Google Scholar
• Storm G, Ten Kate MT, Working PK, et al. doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res. 1998;4(1):111–115.
   PubMed Web of Science ®Google Scholar
• Őrfi E, Mészáros T, Hennies M, et al. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice. Int J Nanomedicine. 2019;14:1563–1573.
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163–173.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, de Haan LHJ, Evers NM, et al. Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells. Part Fibre Toxicol. 2010;7(1):25.
   PubMedGoogle Scholar
• Gustafson HH, Holt-Casper D, Grainger DW, et al. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487–510.
   PubMed Web of Science ®Google Scholar
• Lara S, Perez-Potti A, Herda LM, et al. Differential recognition of nanoparticle protein corona and modified low-density lipoprotein by macrophage receptor with collagenous structure. ACS Nano. 2018;12(5):4930–4937.
   PubMed Web of Science ®Google Scholar
• Moyano DF, Saha K, Prakash G, et al. Fabrication of corona-free nanoparticles with tunable hydrophobicity. ACS Nano. 2014;8(7):6748–6755.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Lee B-J. Protein corona: a new approach for nanomedicine design. Int J Nanomedicine. 2017;12:3137–3151.
   PubMed Web of Science ®Google Scholar
• Li B, Lane LA. Probing the biological obstacles of nanomedicine with gold nanoparticles. WIREs Nanomed Nanobiotechnol. 2019;11(3):e1542.
   PubMed Web of Science ®Google Scholar
• Fröhlich E. Comparison of conventional and advanced in vitro models in the toxicity testing of nanoparticles. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1091–1107.
   PubMed Web of Science ®Google Scholar
• Auría-Soro C, Nesma T, Juanes-Velasco P, et al. Interactions of nanoparticles and biosystems: microenvironment of nanoparticles and biomolecules in nanomedicine. Nanomaterials. 2019;9(10):1365.
   Web of Science ®Google Scholar
• Singh AV, Laux P, Luch A, et al. Review of emerging concepts in nanotoxicology: opportunities and challenges for safer nanomaterial design. Toxicol Mech Methods. 2019;29(5):378–387.
   PubMed Web of Science ®Google Scholar
• De Simone U, Roccio M, Gribaldo L, et al. Human 3D cultures as models for evaluating magnetic nanoparticle CNS cytotoxicity after short- and repeated long-term exposure. Int J Mol Sci. 2018;19(7):1993.
   Web of Science ®Google Scholar
• Jain P, Pawar RS, Pandey RS, et al. In-vitro in-vivo correlation (IVIVC) in nanomedicine: is protein corona the missing link? Biotechnol Adv. 2017;35(7): 889–904.
   PubMed Web of Science ®Google Scholar
• Maeda H, Tsukigawa K, Fang J. A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy—problems, solutions, and prospects. Microcirculation. 2016;23(3):173–182.
   PubMed Web of Science ®Google Scholar
• Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer. 1984;49(4):405–413.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664.
   PubMed Web of Science ®Google Scholar
• Greller LD, Tobin FL, Poste G. Tumor heterogeneity and progression: conceptual foundations for modeling. Invasion Metastasis. 1996;16(4–5):177–208.
   PubMedGoogle Scholar
• LeBleu VS. Imaging the tumor microenvironment. Cancer J. 2015;21(3):174–178.
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal Doxorubicin versus Doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445–2451.
   PubMed Web of Science ®Google Scholar
• Kidd J, Jadia R, Velpurisiva P, et al. Targeting strategies for the combination treatment of cancer using drug delivery systems. Pharmaceutics. 2017;9(4):46.
   Web of Science ®Google Scholar
• Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 2017;12:935–947.
   PubMed Web of Science ®Google Scholar
• Baker DE, Levien TL. Irinotecan liposome injection. Hosp Pharm. 2017;52(2):144–150.
   PubMedGoogle Scholar
• Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine. 2018;13:3921–3935.
   PubMed Web of Science ®Google Scholar
• Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9:1370.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8(4):1172–1181.
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):198–205.
   PubMed Web of Science ®Google Scholar
• Bae S, Ma K, Kim TH, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials. 2012;33(5):1536–1546.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Clergeaud G, Andresen TL, et al. Micromotors for drug delivery in vivo: the road ahead. Adv Drug Deliv Rev. 2019;138:41–55.
   PubMed Web of Science ®Google Scholar
• Jones RT. Blood flow. Annu Rev Fluid Mech. 1969;1(1):223–244.
   Google Scholar
• Shurbaji S, Anlar G, Hussein E, et al. Effect of flow-induced shear stress in nanomaterial uptake by cells: focus on targeted anti-cancer therapy. Cancers (Basel). 2020;12:7.
   Web of Science ®Google Scholar
• Hermann J, DiStasio RA, Tkatchenko A. First-principles models for van der Waals interactions in molecules and materials: concepts, theory, and applications. Chem Rev. 2017;117(6):4714–4758.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Popović Z, Chen O, et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed. 2011;50(48):11417–11420.
   PubMed Web of Science ®Google Scholar
• Park JH, von Maltzahn G, Zhang L, et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater. 2008;20(9):1630–1635.
   PubMed Web of Science ®Google Scholar
• Cuddapah VA, Zhang SL, Sehgal A. Regulation of the blood–brain barrier by circadian rhythms and sleep. Trends Neurosci. 2019;42(7):500–510.
   PubMed Web of Science ®Google Scholar
• Etame AB, Smith CA, Chan WC, et al. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine. 2011;7(6): 992–1000.
   PubMed Web of Science ®Google Scholar
• Aldea M, Florian IA, Kacso G, et al. Nanoparticles for targeting intratumoral hypoxia: exploiting a potential weakness of glioblastoma. Pharm Res. 2016;33(9):2059–2077.
   PubMed Web of Science ®Google Scholar
• Lee C, Hwang HS, Lee S, et al. Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv Mater. 2017;29(13):1605563.
   Web of Science ®Google Scholar
• Song B, Liu J, Feng X, et al. A review on potential neurotoxicity of titanium dioxide nanoparticles. Nanoscale Res Lett. 2015;10(1):1042.
   PubMed Web of Science ®Google Scholar
• Liao C, Li Y, Tjong SC. Bactericidal and cytotoxic properties of silver nanoparticles. Int J Mol Sci. 2019;20(2):449.
   PubMed Web of Science ®Google Scholar
• Hopkins LE, Patchin ES, Chiu P-L, et al. Nose-to-brain transport of aerosolised quantum dots following acute exposure. Nanotoxicology. 2014;8(8):885–893.
   PubMed Web of Science ®Google Scholar
• Simkó M, Mattsson M-O. Interactions between nanosized materials and the brain. Curr Med Chem. 2014;21(37):4200–4214.
   PubMed Web of Science ®Google Scholar
• Teleanu DM, Chircov C, Grumezescu AM, et al. Impact of nanoparticles on brain health: an up to date overview. J Clin Med. 2018;7(12):490.
   PubMed Web of Science ®Google Scholar
• Ou H, Cheng T, Zhang Y, et al. Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells. Acta Biomater. 2018;65:339–348.
   PubMed Web of Science ®Google Scholar
• Wang J-Y, Chen J, Yang J, et al. Effects of surface charges of gold nanoclusters on long-term in vivo biodistribution, toxicity, and cancer radiation therapy. Int J Nanomedicine. 2016;11:3475–3485.
   PubMed Web of Science ®Google Scholar
• Deng Y, Saucier-Sawyer JK, Hoimes CJ, et al. The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials. 2014;35(24):6595–6602.
   PubMed Web of Science ®Google Scholar
• Mizuhara T, Saha K, Moyano DF, et al. Acylsulfonamide-functionalized zwitterionic gold nanoparticles for enhanced cellular uptake at tumor pH. Angew Chem Int Ed. 2015;54(22):6567–6570.
   PubMed Web of Science ®Google Scholar
• Teleanu DM, Chircov C, Grumezescu AM, et al. Blood-brain delivery methods using nanotechnology. Pharmaceutics. 2018;10(4): 269.
   PubMed Web of Science ®Google Scholar
• Kou L, Bhutia YD, Yao Q, et al. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front Pharmacol. 2018;9:27.
   PubMed Web of Science ®Google Scholar
• Alexander A, Agrawal M, Uddin A, et al. Recent expansions of novel strategies towards the drug targeting into the brain. Int J Nanomedicine. 2019;14:5895–5909.
   PubMed Web of Science ®Google Scholar
• Hoyos-Ceballos GP, Ruozi B, Ottonelli I, et al. PLGA-PEG-ANG-2 nanoparticles for blood-brain barrier crossing: proof-of-concept study. Pharmaceutics. 2020;12(1):72.
   Web of Science ®Google Scholar
• Ahlawat J, Guillama Barroso G, Masoudi Asil S, et al. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. ACS Omega. 2020;5(22):12583–12595.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Guan J, Jiang Z, et al. Brain-targeted drug delivery by manipulating protein corona functions. Nat Commun. 2019;10(1):3561.
   PubMedGoogle Scholar
• Khongkow M, Yata T, Boonrungsiman S, et al. Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood–brain barrier penetration. Sci Rep. 2019;9(1):8278.
   PubMedGoogle Scholar
• Wu M, Chen W, Chen Y, et al. Focused ultrasound-augmented delivery of biodegradable multifunctional nanoplatforms for imaging-guided brain tumor treatment. Adv Sci. 2018;5(4):1700474.
   Web of Science ®Google Scholar
• Choi M, Ku T, Chong K, et al. Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability. Proc Natl Acad Sci. USA. 2011;108(22):9256.
   PubMed Web of Science ®Google Scholar
• Gong W, Wang Z, Liu N, et al. Improving efficiency of adriamycin crossing blood brain barrier by combination of thermosensitive liposomes and hyperthermia. Biol Pharm Bull. 2011;34(7):1058–1064.
   PubMed Web of Science ®Google Scholar
• Han L, Kong DK, Zheng M-Q, et al. Increased nanoparticle delivery to brain tumors by autocatalytic priming for improved treatment and imaging. ACS Nano. 2016;10(4):4209–4218.
   PubMed Web of Science ®Google Scholar
• Kim D-G, Bynoe MS. A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier. J Clin Invest. 2016;126(5):1717–1733.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Gaspar MM, Scholz D, et al. Track analysis of the passage of rhodamine-labeled liposomes across porcine jejunal mucus in a microchannel device. Ther Deliv. 2018;9(6):419–433.
   PubMed Web of Science ®Google Scholar
• Duncan GA, Jung J, Hanes J, et al. The mucus barrier to inhaled gene therapy. Mol Ther. 2016;24(12):2043–2053.
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnürch A, Steininger S. Synthesis and characterisation of mucoadhesive thiolated polymers. Int J Pharm. 2000;194(2):239–247.
   PubMed Web of Science ®Google Scholar
• Imperiale JC, Nejamkin P, Del Sole MJ, et al. Novel protease inhibitor-loaded nanoparticle-in-microparticle delivery system leads to a dramatic improvement of the oral pharmacokinetics in dogs. Biomaterials. 2015;37:383–394.
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang -Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158–171.
   PubMed Web of Science ®Google Scholar
• Pereira de Sousa I, Steiner C, Schmutzler M, et al. Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles. Eur J Pharm Biopharm. 2015;97:273–279.
   PubMed Web of Science ®Google Scholar
• Sosnik A, Das Neves J, Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review. Prog Polym Sci. 2014;39(12):2030–2075.
   Web of Science ®Google Scholar
• Wang -Y-Y, Lai SK, Suk JS, et al. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew Chem Int Ed. 2008;47(50):9726–9729.
   PubMed Web of Science ®Google Scholar
• Groo A-C, Mircheva K, Bejaud J, et al. Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules. Pharm Res. 2014;31(7):1753–1765.
   PubMed Web of Science ®Google Scholar
• Takatsuka S, Morita T, Koguchi A, et al. Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Int J Pharm. 2006;316(1):124–130.
   PubMedGoogle Scholar
• Müller C, Perera G, König V, et al. Development and in vivo evaluation of papain-functionalized nanoparticles. Eur J Pharm Biopharm. 2014;87(1):125–131.
   PubMed Web of Science ®Google Scholar
• Pereira de Sousa I, Cattoz B, Wilcox MD, et al. Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier. Eur J Pharm Biopharm. 2015;97:257–264.
   PubMed Web of Science ®Google Scholar
• Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev. 2007;8(1):24–29.
   PubMed Web of Science ®Google Scholar
• Siddhanta S, Bhattacharjee S, Harrison SM, et al. Shedding light on the trehalose-enabled mucopermeation of nanoparticles with label-free Raman spectroscopy. Small. 2019;15(33): 1901679.
   Web of Science ®Google Scholar
• Zanin M, Baviskar P, Webster R, et al. The Interaction between respiratory pathogens and mucus. Cell Host Microbe. 2016;19(2):159–168.
   PubMed Web of Science ®Google Scholar
• Lee M-K. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics. 2020;12:3.
   Web of Science ®Google Scholar
• Olusanya TOB, Haj Ahmad RR, Ibegbu DM, et al. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):907.
   PubMed Web of Science ®Google Scholar
• Stratilo CW, Jager S, Crichton M, et al. Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax. PLoS One. 2020;15(1):e0228162.
   PubMed Web of Science ®Google Scholar
• Bolla PK, Meraz CA, Rodriguez VA, et al. Clotrimazole loaded Ufosomes for topical delivery: formulation development and in-vitro studies. Molecules. 2019;24(17):17.
   Web of Science ®Google Scholar
• Nosova AS, Koloskova OO, Nikonova AA, et al. Diversity of PEGylation methods of liposomes and their influence on RNA delivery. MedChemComm. 2019;10(3):369–377.
   PubMed Web of Science ®Google Scholar
• Kacar G. Molecular understanding of interactions, structure, and drug encapsulation efficiency of pluronic micelles from dissipative particle dynamics simulations. Colloid Polymer Sci. 2019;297(7):1037–1051.
   Web of Science ®Google Scholar
• Harada A, Kataoka K. Polyion complex micelle formation from double-hydrophilic block copolymers composed of charged and non-charged segments in aqueous media. Polym J. 2018;50(1):95–100.
   Web of Science ®Google Scholar
• Wang J, Li S, Han Y, et al. Poly(ethylene glycol)–polylactide micelles for cancer therapy. Front Pharmacol. 2018;9:202.
   PubMed Web of Science ®Google Scholar
• Hassankhani Rad A, Asiaee F, Jafari S, et al. Poly(ethylene glycol)-poly(ε-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin. BioImpacts. 2020;10(2):87–95.
   PubMed Web of Science ®Google Scholar
• Yang T, Li W, Duan X, et al. Preparation of two types of polymeric micelles based on poly(β-L-malic acid) for antitumor drug delivery. PLoS One. 2016;11(9):e0162607.
   PubMed Web of Science ®Google Scholar
• Ugarenko M, Chan CK, Nudelman A, et al. Development of pluronic micelle-encapsulated Doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy. Oncol Res. 2009;17(7):283–299.
   PubMed Web of Science ®Google Scholar
• He X, Li L, Su H, et al. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery. Int J Nanomedicine. 2015;10:1791–1804.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Kawano K, Yokoyama M, et al. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm. 2006;308(1–2):183–189.
   PubMedGoogle Scholar
• Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol. 2014;5:77.
   PubMed Web of Science ®Google Scholar
• Deng S, Wu Q, Zhao Y, et al. Biodegradable polymeric micelle-encapsulated Doxorubicin suppresses tumor metastasis by killing circulating tumor cells. Nanoscale. 2015;7(12):5270–5280.
   PubMed Web of Science ®Google Scholar
• Diezi TA, Takemoto JK, Davies NM, et al. Pharmacokinetics and nephrotoxicity of amphotericin B-incorporated poly(ethylene glycol)-block-poly(N-hexyl stearate L-aspartamide) micelles. J Pharm Sci. 2011;100(6):2064–2070.
   PubMed Web of Science ®Google Scholar
• Forrest ML, Won C-Y, Malick AW, et al. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. J Control Release. 2006;110(2):370–377.
   PubMed Web of Science ®Google Scholar
• Aliabadi HM, Mahmud A, Sharifabadi AD, et al. Micelles of methoxy poly(ethylene oxide)-b-poly(ɛ-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J Control Release. 2005;104(2):301–311.
   PubMed Web of Science ®Google Scholar
• Lim DW, Yeom YI, Park TG. Poly(DMAEMA-NVP)-b-PEG-galactose as gene delivery vector for hepatocytes. Bioconjug Chem. 2000;11(5):688–695.
   PubMed Web of Science ®Google Scholar
• Chauhan AS. Dendrimers for drug delivery. Molecules. 2018;23(4):938.
   PubMed Web of Science ®Google Scholar
• Arseneault M, Wafer C, Morin J-F. Recent advances in click chemistry applied to dendrimer synthesis. Molecules. 2015;20(5):9263–9294.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhu M, Li Y, et al. Radiolabeled dendrimers for nuclear medicine applications. Molecules. 2017;22(9):1350.
   PubMed Web of Science ®Google Scholar
• Otis JB, Zong H, Kotylar A, et al. Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells. Oncotarget. 2016;7(24):36002–36013.
   PubMedGoogle Scholar
• Gürbüz MU, Öztürk K, Ertürk AS, et al. Cytotoxicity and biodistribution studies on PEGylated EDA and PEG cored PAMAM dendrimers. J Biomater Sci Polym Ed. 2016;27(16):1645–1658.
   PubMed Web of Science ®Google Scholar
• Han S, Ganbold T, Bao Q, et al. Sugar functionalized synergistic dendrimers for biocompatible delivery of nucleic acid therapeutics. Polymers. 2018;10(9):9.
   Web of Science ®Google Scholar
• Chanphai P, Thomas TJ, Tajmir-Riahi HA. Application and biomolecular study of functionalized folic acid-dendrimer nanoparticles in drug delivery. J Biomol Struct Dyn. 2020;1–8. DOI:10.1080/07391102.2020.1717994
   Web of Science ®Google Scholar
• Rostami I, Zhao Z, Wang Z, et al. Peptide-conjugated PEGylated PAMAM as a highly affinitive nanocarrier towards HER2-overexpressing cancer cells. RSC Adv. 2016;6(109):107337–107343.
   Web of Science ®Google Scholar
• Zhang M, Zhu J, Zheng Y, et al. Doxorubicin-conjugated PAMAM dendrimers for pH-responsive drug release and folic acid-targeted cancer therapy. Pharmaceutics. 2018;10(3):162.
   Web of Science ®Google Scholar
• Rengaraj A, Subbiah B, Haldorai Y, et al. PAMAM/5-fluorouracil drug conjugate for targeting E6 and E7 oncoproteins in cervical cancer: a combined experimental/in silico approach. RSC Adv. 2017;7(9):5046–5054.
   Web of Science ®Google Scholar
• Singh J, Jain K, Mehra NK, et al. Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers. Artif Cells Nanomed Biotechnol. 2016;44(7):1626–1634.
   PubMed Web of Science ®Google Scholar
• Pedro-Hernández LD, Martínez-Klimova E, Cortez-Maya S, et al. Synthesis, characterization, and nanomedical applications of conjugates between resorcinarene-dendrimers and ibuprofen. Nanomaterials. 2017;7(7):163.
   Web of Science ®Google Scholar
• da Silva Santos S, Igne Ferreira E, Giarolla J. Dendrimer prodrugs. Molecules. 2016;21(6):686.
   Web of Science ®Google Scholar
• Kretzmann JA, Ho D, Evans CW, et al. Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA. Chem Sci. 2017;8(4):2923–2930.
   PubMed Web of Science ®Google Scholar
• Sunoqrot S, Bugno J, Lantvit D, et al. Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Control Release. 2014;191:115–122.
   PubMed Web of Science ®Google Scholar
• Mandal AK. Dendrimers in targeted drug delivery applications: a review of diseases and cancer. Int J Polym Mater. 2020;1–11. DOI:10.1080/00914037.2020.1713780
   Web of Science ®Google Scholar
• D’Emanuele A, Jevprasesphant R, Penny J, et al. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004;95(3):447–453.
   PubMed Web of Science ®Google Scholar
• Lancina MG 3rd, Yang H. Dendrimers for ocular drug delivery. Can J Chem. 2017;95(9):897–902.
   PubMed Web of Science ®Google Scholar
• Yavuz B, Pehlivan SB, Unlü N. Dendrimeric systems and their applications in ocular drug delivery. Sci World J. 2013;2013:732340.
   Google Scholar
• Koç FE, Senel M. Solubility enhancement of non-steroidal anti-inflammatory drugs (NSAIDs) using polypolypropylene oxide core PAMAM dendrimers. Int J Pharm. 2013;451(1–2):18–22.
   PubMedGoogle Scholar
• Zakrewsky M, Kumar S, Mitragotri S. Nucleic acid delivery into skin for the treatment of skin disease: proofs-of-concept, potential impact, and remaining challenges. J Control Release. 2015;219:445–456.
   PubMed Web of Science ®Google Scholar
• Rupp R, Rosenthal SL, Stanberry LR. VivaGelTM (SPL7013 gel): a candidate dendrimer - microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine. 2007;2(4):561–566.
   PubMed Web of Science ®Google Scholar
• Lesniak WG, Mishra MK, Jyoti A, et al. Biodistribution of fluorescently labeled PAMAM dendrimers in neonatal rabbits: effect of neuroinflammation. Mol Pharm. 2013;10(12):4560–4571.
   PubMedGoogle Scholar
• Peng Z, Liu X, Zhang W, et al. Advances in the application, toxicity and degradation of carbon nanomaterials in environment: a review. Environ Int. 2020;134:105298.
   PubMed Web of Science ®Google Scholar
• Manzetti S, Gabriel J-CP. Methods for dispersing carbon nanotubes for nanotechnology applications: liquid nanocrystals, suspensions, polyelectrolytes, colloids and organization control. Int Nano Lett. 2019;9(1):31–49.
   Web of Science ®Google Scholar
• Yan Y, Wang R, Hu Y, et al. Stacking of Doxorubicin on folic acid-targeted multi-walled carbon nanotubes for in vivo chemotherapy of tumors. Drug Deliv. 2018;25(1):1607–1616.
   PubMed Web of Science ®Google Scholar
• Wolski P, Nieszporek K, Panczyk T. Pegylated and folic acid functionalized carbon nanotubes as pH controlled carriers of doxorubicin. Molecular dynamics analysis of the stability and drug release mechanism. Phys Chem Chem Phys. 2017;19(13):9300–9312.
   PubMed Web of Science ®Google Scholar
• Roy S, Petrova RS, Mitra S. Effect of carbon nanotube (CNT) functionalization in epoxy-CNT composites. Nanotechnol Rev. 2018;7(6):475–485.
   PubMed Web of Science ®Google Scholar
• Santos AC, Pereira I, Reis S, et al. Biomedical potential of clay nanotube formulations and their toxicity assessment. Exp Opin Drug Deliv. 2019;16(11):1169–1182.
   PubMed Web of Science ®Google Scholar
• Menezes B, Rodrigues KF, Fonseca B, et al. Recent advances in the use of carbon nanotubes as smart biomaterials. J Mater Chem B. 2019;7(9):1343–1360.
   PubMed Web of Science ®Google Scholar
• Niu L, Meng L, Lu Q. Folate-conjugated PEG on single walled carbon nanotubes for targeting delivery of doxorubicin to cancer cells. Macromol Biosci. 2013;13(6):735–744.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68(16):6652.
   PubMed Web of Science ®Google Scholar
• Hampel S, Kunze D, Haase D, et al. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine. 2008;3(2):175–182.
   PubMed Web of Science ®Google Scholar
• Wu W, Li R, Bian X, et al. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano. 2009;3(9):2740–2750.
   PubMed Web of Science ®Google Scholar
• Gu Y-J, Cheng J, Jin J, et al. Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells. Int J Nanomedicine. 2011;6:2889–2898.
   PubMed Web of Science ®Google Scholar
• Ding X, Su Y, Wang C, et al. Synergistic suppression of tumor angiogenesis by the co-delivering of vascular endothelial growth factor targeted siRNA and candesartan mediated by functionalized carbon nanovectors. ACS Appl Mater Interfaces. 2017;9(28):23353–23369.
   PubMed Web of Science ®Google Scholar
• Hussey SL, Peterson BR. Efficient delivery of streptavidin to mammalian cells: clathrin-mediated endocytosis regulated by a synthetic ligand. J Am Chem Soc. 2002;124(22):6265–6273.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Villa CH, Holland JP, et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine. 2010;5:783–802.
   PubMed Web of Science ®Google Scholar
• Singh R, Torti SV. Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev. 2013;65(15):2045–2060.
   PubMed Web of Science ®Google Scholar
• Sireesha M, Jagadeesh Babu V, Kranthi Kiran AS, et al. A review on carbon nanotubes in biosensor devices and their applications in medicine. Nanocomposites. 2018;4(2):36–57.
   Web of Science ®Google Scholar
• Palanisamy S, Wang Y-M. Superparamagnetic iron oxide nanoparticulate system: synthesis, targeting, drug delivery and therapy in cancer. Dalton Trans. 2019;48(26):9490–9515.
   PubMed Web of Science ®Google Scholar
• Dulińska-Litewka J, Łazarczyk A, Hałubiec P, et al. Superparamagnetic iron oxide nanoparticles-current and prospective medical applications. Materials. 2019;12(4):617.
   Web of Science ®Google Scholar
• Feng Q, Liu Y, Huang J, et al. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci Rep. 2018;8(1):2082.
   PubMedGoogle Scholar
• Patsula V, Horák D, Kučka J, et al. Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model. Sci Rep. 2019;9(1):10765.
   PubMed Web of Science ®Google Scholar
• Villa S, Riani P, Locardi F, et al. Functionalization of Fe3O4 NPs by silanization: use of amine (APTES) and thiol (MPTMS) silanes and their physical characterization. Materials. 2016;9(10):826.
   Web of Science ®Google Scholar
• Bemowsky S, Rother A, Willmann W, et al. Quantification and biodegradability assessment of meso-2,3-dimercaptosuccinic acid adsorbed on iron oxide nanoparticles. Nanoscale Adv. 2019;1(9):3670–3679.
   Web of Science ®Google Scholar
• Janßen HC, Angrisani N, Kalies S, et al. Biodistribution, biocompatibility and targeted accumulation of magnetic nanoporous silica nanoparticles as drug carrier in orthopedics. J Nanobiotechnol. 2020;18(1):14.
   PubMed Web of Science ®Google Scholar
• Moraes Silva S, Tavallaie R, Sandiford L, et al. Gold coated magnetic nanoparticles: from preparation to surface modification for analytical and biomedical applications. Chem Commun. 2016;52(48):7528–7540.
   PubMed Web of Science ®Google Scholar
• Bao Y, Wen T, Samia ACS, et al. Magnetic nanoparticles: material engineering and emerging applications in lithography and biomedicine. J Mater Sci. 2016;51(1):513–553.
   PubMed Web of Science ®Google Scholar
• Mimun LC, Ajithkumar G, Rightsell C, et al. Synthesis and characterization of Na(Gd0.5Lu0.5)F4: nd3+,a core-shell free multifunctional contrast agent. J Alloys Compd. 2017;695:280–285.
   PubMed Web of Science ®Google Scholar
• Rouhollah K, Pelin M, Serap Y, et al. Doxorubicin loading, release, and stability of polyamidoamine dendrimer-coated magnetic nanoparticles. J Pharm Sci. 2013;102(6):1825–1835.
   PubMed Web of Science ®Google Scholar
• Lübbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4ʹ-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56(20):4686–4693.
   PubMed Web of Science ®Google Scholar
• Reczyńska K, Marchwica P, Khanal D, et al. Stimuli-sensitive fatty acid-based microparticles for the treatment of lung cancer. Mater Sci Eng C. 2020;111:110801.
   PubMed Web of Science ®Google Scholar
• Pirmardvand Chegini S, Varshosaz J, Taymouri S. Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment. Artif Cells Nanomed Biotechnol. 2018;46(sup2):502–514.
   PubMed Web of Science ®Google Scholar
• Ashjari M, Khoee S, Mahdavian AR. A multiple emulsion method for loading 5-fluorouracil into a magnetite-loaded nanocapsule: a physicochemical investigation. Polym Int. 2012;61(5):850–859.
   Web of Science ®Google Scholar
• Truffi M, Colombo M, Sorrentino L, et al. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells. Sci Rep. 2018;8(1):6563.
   PubMedGoogle Scholar
• Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62(1):3–16.
   PubMed Web of Science ®Google Scholar
• Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics. 2016;8(2):16.
   PubMed Web of Science ®Google Scholar
• Liu T, Yu X, Yin H, et al. Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery. Drug Deliv. 2019;26(1):1092–1103.
   PubMed Web of Science ®Google Scholar
• Jarvis M, Krishnan V, Mitragotri S. Nanocrystals: A perspective on translational research and clinical studies. Bioeng Transl Med. 2018;4(1):5–16.
   PubMed Web of Science ®Google Scholar
• Huang Y-W, Cambre M, Lee H-J. The toxicity of nanoparticles depends on multiple molecular and physicochemical mechanisms. Int J Mol Sci. 2017;18(12):2702.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Sarode A, Bhatt R, et al. Surface-functionalized carrier-free drug nanorods for leukemia. Adv Ther. 2018;1(2):1800010.
   Google Scholar
• Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci. 2006;103(13):4930–4934.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu H, Zhang H, et al. Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis. Nanoscale. 2015;7(24):10790–10800.
   PubMed Web of Science ®Google Scholar
• Zhan H, Jagtiani T, Liang JF. A new targeted delivery approach by functionalizing drug nanocrystals through polydopamine coating. Eur J Pharm Biopharm. 2017;114:221–229.
   PubMed Web of Science ®Google Scholar
• Date AA, Halpert G, Babu T, et al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018;185:97–105.
   PubMed Web of Science ®Google Scholar
• Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2(11):1903–1917.
   PubMedGoogle Scholar
• Tang H, Zhao W, Yu J, et al. Recent development of pH-responsive polymers for cancer nanomedicine. Molecules. 2018;24(1):4.
   PubMed Web of Science ®Google Scholar
• V NSKV, H GS, Fathima SJ, et al. pH and thermosensitive 5-fluorouracil loaded poly(NIPAM-co-AAc) nanogels for cancer therapy. RSC Adv. 2016;6(107):105495–105507.
   Web of Science ®Google Scholar
• de Oliveira Silva J, Fernandes RS, Ramos Oda CM, et al. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model. Biomed Pharmacother. 2019;118:109323.
   PubMed Web of Science ®Google Scholar
• Paliwal SR, Paliwal R, Vyas SP. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Deliv. 2015;22(3):231–242.
   PubMed Web of Science ®Google Scholar
• Quach ND, Arnold RD, Cummings BS. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol. 2014;90(4):338–348.
   PubMed Web of Science ®Google Scholar
• Foged C, Nielsen HM, Frokjaer S. Liposomes for phospholipase A2 triggered siRNA release: preparation and in vitro test. Int J Pharm. 2007;331(2):160–166.
   PubMed Web of Science ®Google Scholar
• Zhu G, Mock JN, Aljuffali I, et al. Secretory phospholipase A2 responsive liposomes. J Pharm Sci. 2011;100(8):3146–3159.
   PubMed Web of Science ®Google Scholar
• Hu X, Li D, Zhang W, et al. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286(6):1537–1543.
   PubMed Web of Science ®Google Scholar
• Sarkar NR, Rosendahl T, Krueger AB, et al. “Uncorking” of liposomes by matrix metalloproteinase-9. Chem Commun. 2005; (8):999–1001. DOI:10.1039/B416827E.
   PubMed Web of Science ®Google Scholar
• Elegbede AI, Banerjee J, Hanson AJ, et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc. 2008;130(32):10633–10642.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Neumann O, Nørregaard K, et al. Near-infrared remotely triggered drug-release strategies for cancer treatment. Proc Natl Acad Sci USA. 2017;114(47):12419.
   PubMed Web of Science ®Google Scholar
• Mena-Giraldo P, Pérez-Buitrago S, Londoño-Berrío M, et al. Photosensitive nanocarriers for specific delivery of cargo into cells. Sci Rep. 2020;10(1):2110.
   PubMed Web of Science ®Google Scholar
• Yavlovich A, Singh A, Blumenthal R, et al. A novel class of photo-triggerable liposomes containing DPPC:DC8,9PC as vehicles for delivery of doxorubicin to cells. Biochim Biophys Acta Biomembr. 2011;1808(1):117–126.
   Web of Science ®Google Scholar
• Ta T, Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release. 2013;169(1–2):112–125.
   PubMed Web of Science ®Google Scholar
• Chen W, Duša F, Witos J, et al. Determination of the main phase transition temperature of phospholipids by nanoplasmonic sensing. Sci Rep. 2018;8(1):14815.
   PubMedGoogle Scholar
• Smith B, Lyakhov I, Loomis K, et al. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes). J Control Release. 2011;153(2):187–194.
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, et al. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387–4398.
   PubMed Web of Science ®Google Scholar
• Mazzotta E, Tavano L, Muzzalupo R. Thermo-sensitive vesicles in controlled drug delivery for chemotherapy. Pharmaceutics. 2018;10(3):150.
   Web of Science ®Google Scholar
• Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev. 2001;53(3):307–319.
   PubMed Web of Science ®Google Scholar
• Chandaroy P, Sen A, Hui SW. Temperature-controlled content release from liposomes encapsulating Pluronic F127. J Control Release. 2001;76(1–2):27–37.
   PubMed Web of Science ®Google Scholar
• Tharkar P, Varanasi R, Wong WSF, et al. Nano-enhanced drug delivery and therapeutic ultrasound for cancer treatment and beyond. Front Bioeng Biotechnol. 2019;7:324.
   PubMed Web of Science ®Google Scholar
• Huang SL. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1167–1176.
   PubMed Web of Science ®Google Scholar
• Evjen TJ, Nilssen EA, Fowler RA, et al. Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. Int J Pharm. 2011;406(1):114–116.
   PubMedGoogle Scholar
• Klibanov AL, Shevchenko TI, Raju BI, et al. Ultrasound-triggered release of materials entrapped in microbubble-liposome constructs: a tool for targeted drug delivery. J Control Release. 2010;148(1):13–17.
   PubMed Web of Science ®Google Scholar
• Abbasi E, Kafshdooz T, Bakhtiary M, et al. Biomedical and biological applications of quantum dots. Artif Cells Nanomed Biotechnol. 2016;44(3):885–891.
   PubMed Web of Science ®Google Scholar
• Gimenez Y, Busser B, Trichard F, et al. 3D Imaging of nanoparticle distribution in biological tissue by laser-induced breakdown spectroscopy. Sci Rep. 2016;6(1):29936.
   PubMedGoogle Scholar
• Feng J, Xu Z, Luo D, et al. Multiplexed imaging with coordination nanoparticles for cancer diagnosis and therapy. ACS Appl Biomater. 2020;3(1):713–720.
   Google Scholar
• Li X, Zhang X-N, Li X-D, et al. Multimodality imaging in nanomedicine and nanotheranostics. Cancer Biol Med. 2016;13(3):339–348.
   PubMed Web of Science ®Google Scholar
• Michenfelder MM, Bartlett LJ, Mahoney DW, et al. Particle-size and radiochemical purity evaluations of filtered 99mTc-Sulfur colloid prepared with different heating times. J Nucl Med Technol. 2014;42(4):283–288.
   PubMedGoogle Scholar
• Thakor AS, Jokerst JV, Ghanouni P, et al. Clinically approved nanoparticle imaging agents. J Nucl Med. 2016;57(12):1833–1837.
   PubMed Web of Science ®Google Scholar
• Whitman GJ, AlHalawani RH, Karbasian N, et al. Sentinel lymph node evaluation: what the radiologist needs to know. Diagnostics. 2019;9(1):12.
   Web of Science ®Google Scholar
• Tsopelas C. The radiopharmaceutical chemistry of 99mTc-tin fluoride colloid-labeled-leukocytes. Q J Nucl Med Mol Imaging. 2005 Dec;49(4):319–324.
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Sunil HV, Mittal BR, et al. Role of Tc99m sulfur colloid scintigraphy in differentiating non-cirrhotic portal fibrosis from cirrhosis liver. Indian J Nucl Med. 2010;25(4):139–142.
   PubMedGoogle Scholar
• Hood MN, Blankholm AD, Stolpen A. The rise of off-label iron-based agents in magnetic resonance imaging. J Radiol Nurs. 2019;38(1):38–41.
   Google Scholar
• Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676.
   PubMed Web of Science ®Google Scholar
• Kaittanis C, Shaffer TM, Ogirala A, et al. Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching. Nat Commun. 2014;5(1):3384.
   PubMedGoogle Scholar
• Burke BP, Cawthorne C, Archibald SJ. Multimodal nanoparticle imaging agents: design and applications. Philos T R Soc A. 2017;375:2107.
   Google Scholar
• Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011;121(7):2768–2780.
   PubMed Web of Science ®Google Scholar
• Brouwer OR, Buckle T, Vermeeren L, et al. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med. 2012;53(7):1034–1040.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5): 16014.
   Web of Science ®Google Scholar
• McNeil SE. Evaluation of nanomedicines: stick to the basics. Nat Rev Mater. 2016;1(10):16073.
   Web of Science ®Google Scholar
• Price LSL, Stern ST, Deal AM, et al. A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. Sci Adv. 2020;6(29):eaay9249.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim J, Park YI, et al. Recent development of inorganic nanoparticles for biomedical imaging. ACS Cent Sci. 2018;4(3):324–336.
   PubMed Web of Science ®Google Scholar
• Gabizon AA, de Rosales RTM, La-Beck NM. Translational considerations in nanomedicine: the oncology perspective. Adv Drug Deliv Rev. 2020:1–18 Available Online. 10.1016/j.addr.2020.05.012
   Web of Science ®Google Scholar
• Park K. Drug delivery of the future: chasing the invisible gorilla. J Control Release. 2016;240:2–8.
   PubMed Web of Science ®Google Scholar
• Singer AC, Shaw H, Rhodes V, et al. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front Microbiol. 2016;7:1728.
   PubMed Web of Science ®Google Scholar
• Ogunsona EO, Muthuraj R, Ojogbo E, et al. Engineered nanomaterials for antimicrobial applications: A review. Appl Mater Today. 2020;18:100473.
   Web of Science ®Google Scholar
• Lee N-Y, Ko W-C, Hsueh P-R. Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. Front Pharmacol. 2019;10:1153.
   PubMed Web of Science ®Google Scholar
• Wang D-Y, van der Mei HC, Ren Y, et al. Lipid-based antimicrobial delivery-systems for the treatment of bacterial infections. Front Chem. 2020;7:872.
   PubMed Web of Science ®Google Scholar
• González-Paredes A, Sitia L, Ruyra A, et al. Solid lipid nanoparticles for the delivery of anti-microbial oligonucleotides. Eur J Pharm Biopharm. 2019;134:166–177.
   PubMed Web of Science ®Google Scholar
• Kalomiraki M, Thermos K, Chaniotakis NA. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 2015;11:1–12.
   PubMed Web of Science ®Google Scholar
• Dakal TC, Kumar A, Majumdar RS, et al. Mechanistic basis of antimicrobial actions of silver nanoparticles. Front Microbiol. 2016;7:1831.
   PubMed Web of Science ®Google Scholar
• Meghana S, Kabra P, Chakraborty S, et al. Understanding the pathway of antibacterial activity of copper oxide nanoparticles. RSC Adv. 2015;5(16):12293–12299.
   Web of Science ®Google Scholar
• Tiwari V, Mishra N, Gadani K, et al. Mechanism of anti-bacterial activity of zinc oxide nanoparticle against carbapenem-resistant Acinetobacter baumannii. Front Microbiol. 2018;9:1218.
   PubMed Web of Science ®Google Scholar
• Ziental D, Czarczynska-Goslinska B, Mlynarczyk DT, et al. Titanium dioxide nanoparticles: prospects and applications in medicine. Nanomaterials. 2020;10(2):2.
   Web of Science ®Google Scholar
• Al-Jumaili A, Alancherry S, Bazaka K, et al. Review on the antimicrobial properties of carbon nanostructures. Materials. 2017;10(9):1066.
   PubMed Web of Science ®Google Scholar
• Brunet L, Lyon DY, Hotze EM, et al. Comparative photoactivity and antibacterial properties of C60 fullerenes and titanium dioxide nanoparticles. Environ Sci Technol. 2009;43(12):4355–4360.
   PubMed Web of Science ®Google Scholar
• Chen M, Daddy JCKA, Xiao Y, et al. Advanced nanomedicine for rheumatoid arthritis treatment: focus on active targeting. Exp Opin Drug Deliv. 2017;14(10):1141–1144.
   PubMed Web of Science ®Google Scholar
• Bottini M, Bhattacharya K, Fadeel B, et al. Nanodrugs to target articular cartilage: an emerging platform for osteoarthritis therapy. Nanomedicine. 2016;12(2):255–268.
   PubMed Web of Science ®Google Scholar
• Nunes R, Neves J, Sarmento B. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges. Nanomedicine. 2019;14(19):2631–2644.
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224.
   PubMed Web of Science ®Google Scholar
• Kumar A, Pandey AN, Jain SK. Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. 2016;23(3):671–683.
   Web of Science ®Google Scholar
• Dhayani A, Kalita S, Mahato M, et al. Biomaterials for topical and transdermal drug delivery in reconstructive transplantation. Nanomedicine. 2019;14(20):2713–2733.
   PubMed Web of Science ®Google Scholar
• Ahadian S, Finbloom JA, Mofidfar M, et al. Micro and nanoscale technologies in oral drug delivery. Adv Drug Deliv Rev. 2020. Available Online. DOI:10.1016/j.addr.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Giudice V, Mensitieri F, Izzo V, et al. Aptamers and antisense oligonucleotides for diagnosis and treatment of hematological diseases. Int J Mol Sci. 2020;21(9):9.
   Web of Science ®Google Scholar
• Soldevilla MM, Meraviglia-crivelli de Caso D, Menon AP, et al. Aptamer-iRNAs as therapeutics for cancer treatment. Pharmaceuticals. 2018;11(4):108.
   Web of Science ®Google Scholar
• Weng Y, Huang Q, Li C, et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol Ther Nucleic Acids. 2020;19:581–601.
   PubMedGoogle Scholar
• Grodzinski P, Kircher M, Goldberg M, et al. Integrating nanotechnology into cancer care. ACS Nano. 2019;13(7):7370–7376.
   PubMed Web of Science ®Google Scholar
• Chen J, Tang Y, Liu Y, et al. Nucleic acid-based therapeutics for pulmonarydiseases. AAPS PharmSciTech. 2018;19(8):3670–3680.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Shi K, Qu Y, et al. Engineering nanoparticles for targeted delivery of nucleic acid therapeutics in tumor. Mol Ther Methods Clin Dev. 2018;12:1–18.
   PubMed Web of Science ®Google Scholar
• Mokhtarzadeh A, Vahidnezhad H, Youssefian L, et al. Applications of spherical nucleic acid nanoparticles as delivery systems. Trends Mol Med. 2019;25(12):1066–1079.
   PubMed Web of Science ®Google Scholar
• A triumph of perseverance over interference. Nat Biotechnol. 2018;36(9):775.
   PubMed Web of Science ®Google Scholar
• Wei T, Cheng Q, Min Y-L, et al. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232.
   PubMed Web of Science ®Google Scholar
• Afonin KA, Dobrovolskaia MA, Church G, et al. Opportunities, barriers, and a strategy for overcoming translational challenges to therapeutic nucleic acid nanotechnology. ACS Nano. 2020;14(8):9221–9227.
   PubMed Web of Science ®Google Scholar
• Garg S, Heuck G, Ip S, et al. Microfluidics: a transformational tool for nanomedicine development and production. J Drug Target. 2016;24(9):821–835.
   PubMed Web of Science ®Google Scholar
• Yamankurt G, Berns EJ, Xue A, et al. Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat Biomed Eng. 2019;3(4):318–327.
   PubMed Web of Science ®Google Scholar
• Pujals S, Albertazzi L. Super-resolution microscopy for nanomedicine research. ACS Nano. 2019;13(9):9707–9712.
   PubMed Web of Science ®Google Scholar
• Hua S, de Matos MBC, Metselaar JM, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790.
   PubMed Web of Science ®Google Scholar